SCYX

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Wall Street analysts forecast SCYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCYX is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SCYNEXIS Inc revenue for the last quarter amounts to 334.00K USD, decreased -49.39 % YoY.

SCYNEXIS Inc. EPS for the last quarter amounts to -0.17 USD, increased 183.33 % YoY.

SCYNEXIS Inc (SCYX) has 28 emplpoyees as of December 15 2025.

Today SCYX has the market capitalization of 27.11M USD.